15.265 articles found

Glial interaction with Parkinsonian disorders biomarkers: alpha‐synuclein, dopaminergic dysfunction and clinical stages

Souza L, dos Santos D, Zimmer E, Borelli W, Schumacher‐Schuh A.

Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025-12-01

Iron on trial: recasting the role of iron in neurodegeneration.

Ayton S, Moreau C, Devos D, Bush AI.

Brain · 2025-12-01

DOI: 10.1093/brain/awaf398PMID: 41126461

Diagnostic and other biomarkers of dementia with Lewy bodies: from research to clinical settings.

Zarkali A, Bartl M, Fox NC, Tan LCS, Mollenhauer B, Weil RS.

Lancet Neurol · 2025-12-01

DOI: 10.1016/s1474-4422(25)00314-xPMID: 41240920

Phase II pilot randomized trial of zonisamide for disease modification in prodromal Lewy body disease.

Hiraga K, Hattori M, Tamakoshi D, Satake Y, Fukushima T, Saito Y, Uematsu T, Tsuboi T, Sato M, Yokoi K, Suzuki K, Arahata Y, Ueki Y, Kinoshita F, Matsuda H, Murata A, Yamamoto M, Wakai M, Matsukawa N, Washimi Y, Katsuno M.

NPJ Parkinsons Dis · 2025-12-01

DOI: 10.1038/s41531-025-01198-3PMID: 41326428

Phosphodiesterase Inhibition Increases Striatal GDNF and Protects Against Preclinical Parkinsonism.

d'Anglemont de Tassigny X, Jiménez-Medina A, López-López I, López-Barneo J.

J Neurochem · 2025-12-01

DOI: 10.1111/jnc.70321PMID: 41382340

High fear-of-falling in Parkinson's disease: Distinct clinical phenotypes with motor and non-motor dominance.

Onder H, Iscan D, Tunc H, Yavuz Z, Comoglu S.

Parkinsonism Relat Disord · 2025-12-01

DOI: 10.1016/j.parkreldis.2025.108138PMID: 41330134

Machine learning and deep learning in clinical practice: Advancing neurodegenerative disease diagnosis with multimodal markers.

Zarei O, Talebi Moghaddam M, Moradi Vastegani S.

Brain Res Bull · 2025-12-01

DOI: 10.1016/j.brainresbull.2025.111667PMID: 41338440

Foslevodopa/Foscarbidopa in Younger Patients Earlier Within Advanced Parkinson's Disease: Post Hoc Analysis of a Randomized Trial.

Antonini A, Bergmans B, Kern DS, Gandor F, Nishikawa N, Standaert DG, Fritz B, Gupta R, Nozaki T, Shah MB, Bergmann L, Kimber T.

Neurol Ther · 2025-12-01

DOI: 10.1007/s40120-025-00856-1PMID: 41324738

When there is little or no research evidence: a clinical decision tool.

Murphy B, Emary PC, De Ciantis M, Parish JM, Srbely J, Chopra A, Gleberzon B.

J Can Chiropr Assoc · 2025-11-30

PMID: 41425290

Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases.

Girges C, Vijiaratnam N, King A, Auld G, McComish R, Chowdhury K, Ambler G, Maclagan K, Limousin P, Athauda D, Morris HR, Libri V, Foltynie T, Exenatide PD3 and MSA Trials Consortia.

Clin Trials · 2025-11-30

DOI: 10.1177/17407745251387571PMID: 41321006

Telerehabilitation for people with Parkinson's disease: protocol of a randomised clinical trial of mixed methods.

Taveira RS, Vasconcellos LS, Bezerra CF, Aires DN, Dias de Oliveira AK, da Silva KOC, Melo LP, Ribeiro TS.

BMJ Open · 2025-11-29

DOI: 10.1136/bmjopen-2024-096285PMID: 41320221

Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK).

Rascol O, Ory-Magne F, Meissner WG, Maltête D, Defebvre L, Azulay JP, Thobois S, Houeto JL, Thalamas C, Sommet A, Geny C, Damier P, Anheim M, Marquès A, Viallet F, Giroud M, Lefaucheur R, Costentin G, Spampinato U, Samier-Foubert A, Carrière N, Mutez E, Mariani LL, Eusebio A, Prange S, Benatru I, Charif M, Brefel-Courbon C, Fabbri M, Galitzky M, Rousseau V, Saubion A, Catala H, Ferreira JJ, Burn DJ, Corvol JC, PREMANDYSK Study Group.

Mov Disord · 2025-11-29

DOI: 10.1002/mds.70120PMID: 41316871